RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy

BACKGROUND: The expression level of ribonucleotide reductase subunit M1 (RRM1) is closely related to the effect of gemcitabine-based therapy in advanced bladder cancer. However, the value of RRM1 expression in predicting progression-free survival in non-muscle-invasive bladder cancer (NMIBC) patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhenxing, Fu, Bingqiang, Zhou, Luqiang, Xu, Jie, Hao, Ping, Fang, Zhenqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657136/
https://www.ncbi.nlm.nih.gov/pubmed/31340801
http://dx.doi.org/10.1186/s12894-019-0497-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657136/
https://www.ncbi.nlm.nih.gov/pubmed/31340801
http://dx.doi.org/10.1186/s12894-019-0497-x

Ejemplares similares